Is PT-141 FDA-Approved?
Only in one form. Vyleesi®, a bremelanotide injection, is FDA-approved for certain premenopausal women with low sexual desire. Compounded PT-141 is not FDA-approved, no PT-141 product is FDA-approved for men, and PT-141 is not available over the counter. The FDA has called PT-141 sold online for research an unapproved new drug.
Key facts
- The FDA approved Vyleesi® on June 21, 2019, for premenopausal women with acquired, generalized hypoactive sexual desire disorder.
- Compounded PT-141 is not FDA-approved. No nasal or under-the-tongue form of bremelanotide is FDA-approved.
- No PT-141 product is FDA-approved for men.
- PT-141 is not available over the counter. Vyleesi® is a prescription product, and a compounded medicine needs a prescription for an individual patient.
- In August 2026 the FDA sent warning letters to online sellers of research peptides, including PT-141, calling those products unapproved new drugs.
What did the FDA approve?
On June 21, 2019, the FDA approved Vyleesi® (bremelanotide) to treat acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is an injection given under the skin with an autoinjector, and it is a prescription product.
The approval has limits. The Vyleesi® label says it is not indicated for HSDD in postmenopausal women or in men, and not to enhance sexual performance. The FDA's announcement said plainly that Vyleesi® does not enhance sexual performance.
Is compounded PT-141 FDA-approved?
No. FDA approval belongs to a specific product, after its company has shown safety and effectiveness. The trials behind Vyleesi® tested that injection. A compounded spray, tablet or injection is a separate preparation made by a pharmacy, and it has no FDA review of its own.
The FDA says it does not verify the safety, effectiveness or quality of compounded drugs before they are marketed. It also warns that poor compounding practices can cause serious quality problems, such as contamination or too much or too little active ingredient, and that this can lead to serious patient injury and death.
The FDA's position is that compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug. That is a question to raise with your provider, who decides what fits.
Is compounded PT-141 legal?
Compounding is legal when federal and state conditions are met, including a valid prescription for an individual patient. Under section 503A of federal law, when no USP or NF monograph exists, a bulk substance must be a component of an FDA-approved drug product or appear on the FDA's 503A bulks list. Bremelanotide is a component of Vyleesi®, but that is only one condition. The bulk substance must also come with a valid certificate of analysis and be made by an establishment registered with the FDA, and the other conditions of section 503A still apply.
The law also limits compounding of drugs that are essentially copies of a commercially available product. FDA guidance generally treats a drug with a matching active ingredient, a similar strength and the same route of administration as a copy, unless a prescriber determines that a change makes a significant difference for that patient.
The rules on peptides are moving. In July 2026 an FDA advisory committee discussed seven peptides for the 503A bulks list, and in October 2026 HHS issued an interim policy covering six of them. Bremelanotide was not among the seven. None of this makes compounded PT-141 FDA-approved.
Is PT-141 available over the counter?
No. Drugs@FDA lists Vyleesi® as a prescription product, and a compounded medicine is made from a prescription for an individual patient. PT-141 sold with no prescription fits neither route.
Can you buy PT-141 peptide online?
You will find it for sale, and that is a reason for care. On August 24, 2026, the FDA sent warning letters to online peptide sellers that named PT-141. Those sellers labeled their products for research and not for human use. The FDA said their websites showed the products were intended as drugs for people, and it called them unapproved new drugs.
A product labeled for research and not for human use is not a prescription medicine prepared for you. The FDA says buying medicine online from unregulated, unlicensed sources can expose patients to poor-quality products. The same FDA answer says people who buy compounded drugs through online pharmacies and telehealth platforms may not know who compounded the drug, and it encourages them to research the service first. A 2026 review in Sexual Medicine Reviews raises concerns about product quality, dosing variability and poorly understood side effects with peptides such as melanotan II sold through unregulated markets.
Before you order, check that the seller requires a provider evaluation and a prescription, and uses a licensed U.S. pharmacy. The FDA's BeSafeRx pages explain how to check an online pharmacy. The cost page sets out what a prescription plan on CHROMA23® includes, and this comparison covers nasal sprays and injections.
Frequently asked questions
Is PT-141 FDA-approved for men?
No. The FDA-approved bremelanotide product is Vyleesi®, and its label says it is not indicated in men. Use in men is outside the FDA-approved indication.
Is compounded PT-141 the same as Vyleesi®?
No. Vyleesi® is an FDA-approved injection. Compounded PT-141 is prepared by a pharmacy for one patient and is not FDA-approved.
Why would a provider prescribe something that is not FDA-approved?
The FDA says compounded drugs should only be used when an FDA-approved drug cannot meet a patient's needs. Ask your provider why a compounded medicine is being recommended, and whether an FDA-approved option fits you.
Is PT-141 on the FDA's list of risky peptides?
Bremelanotide is not named on the FDA page of bulk substances that may present significant safety risks, as last updated in April 2026. That page does name kisspeptin-10, and it lists melanotan II among substances whose nominations were withdrawn. That page covers substances nominated for the bulks lists, so the absence of bremelanotide from it is not a safety finding, and it does not make a compounded product FDA-approved.
About CHROMA23®
CHROMA23® brings weight loss, longevity, sexual health, hair, and skincare into one place. Every prescription decision is made by an independent provider licensed in the patient's state, where available, and every medication is dispensed by a state-licensed pharmacy. The assessment is free. One clear price per plan, shown in full before you pay. The medicine is real. The provider is real.
Sources
- Vyleesi® (bremelanotide injection) full prescribing information, revised October 2026
- FDA: approval announcement for Vyleesi®, June 21, 2019 (archived copy)
- FDA: approval letter for Vyleesi®, NDA 210557
- Drugs@FDA: Vyleesi®, NDA 210557
- FDA: compounding and the FDA, questions and answers
- FDA: bulk drug substances used in compounding under section 503A
- FDA guidance: compounded drug products that are essentially copies of a commercially available drug product
- FDA: certain bulk drug substances that may present significant safety risks
- Federal Register notice: Pharmacy Compounding Advisory Committee meeting, July 2026
- McDermott: HHS interim policy on six compounded peptides, October 2026
- FDA warning letter to an online peptide seller naming PT-141, August 24, 2026
- FDA warning letter to an online peptide seller naming PT-141, August 24, 2026 (second letter)
- FDA: BeSafeRx, online pharmacy information
- Vasylieva et al.: peptides in urology and sexual medicine, a narrative review (Sexual Medicine Reviews, 2026)
Keep reading
This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Always consult a licensed provider about your individual situation. Figures from named clinical trials describe study populations; individual results vary and are not typical.
PT-141